12:00 AM
 | 
Feb 03, 2014
 |  BC Week In Review  |  Company News  |  Deals

Eureka Therapeutics, Novartis, Memorial Sloan Kettering deal

Eureka and Memorial Sloan Kettering Cancer Center granted Novartis exclusive, worldwide rights to develop and commercialize ESK1, a preclinical mAb against Wilm's Tumor 1 ( WT1) in development for cancer. Eureka and the center will receive an...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >